The American Society for Radiation Oncology (ASTRO) issued new guidance on using radiation therapy to treat grade 4 diffuse gliomas, which account for nearly half of malignant brain tumors in adults ...

The FDA removed the Risk Evaluation and Mitigation Strategies (REMS) requirements for approved BCMA- and CD19-targeting chimeric antigen receptor (CAR) T-cell therapies. The FDA can require a REMS ...

Major Finding: An intraoperative sequencing workflow provides rapid turnaround of comprehensive molecular profiling of central nervous system (CNS) tumors. Concept: Methylation profile and DNA copy ...

Ductal carcinoma in situ (DCIS) is a risk factor for subsequent invasive breast cancer (IBC). To identify events in DCIS that lead to invasive cancer, we performed single-cell RNA sequencing on DCIS ...

Insurance giant Cigna accused Bristol Myers Squibb (BMS) of maintaining a monopoly over Pomalyst (pomalidomide), the pharma company’s $2-billion-a-year immunomodulatory drug for multiple myeloma. In a ...

The NIH will, for now, not cancel additional research grants beyond those that have already been terminated, according to an internal memo from a senior NIH official informing agency staff of the ...

Major Finding: Uptake of exogenous lipoproteins through glycosaminoglycans protects cancer cells from ferroptosis.Concept: Lipoproteins inhibit ferroptosis by delivering α-tocopherol, a form of ...

The FDA gave accelerated approval to datopotamab deruxtecan (Datroway; Daiichi Sankyo), a TROP-2 targeting antibody–drug conjugate (ADC), for patients with advanced or metastatic EGFR-mutated ...

Adding pembrolizumab (Keytruda; Merck) to standard of care improved event-free survival for patients with head and neck squamous-cell carcinoma (HNSCC) in the phase III KEYNOTE-689 study, according to ...

Abstract. Glioblastoma (GBM) is the most common and aggressive malignant brain tumor in adults, with a median survival of ∼15 months. Given the poor survival with the currently approved treatments, ...

AbstractPurpose:. Melanoma brain metastases (MBM) are common in advanced melanoma and linked to poor prognosis. Preventing MBM can improve survival and reduce morbidity. Although dual-agent ...

AbstractCisplatin-based neoadjuvant chemotherapy followed by radical cystectomy is the main treatment for muscle-invasive bladder cancer (MIBC). However, low survival rates highlight the necessity for ...